Related Experiment Video
Updated: Sep 21, 2026
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Analytical comparison of hepatitis B core total antibody serological immunoassays on Atellica and Cobas analyzers
Sarah Donald1, Matthew F W Gee2, Maria E Pagano2
1Clinical Chemistry Research Lab, University of Maryland, Baltimore, MD, United States.
Background:
Serological detection of total antibodies (IgM and IgG) against hepatitis B core antigen (HBc) is essential for diagnosing and assessing infection status of Hepatitis B virus (HBV). Despite multiple commercialized anti‑HBc total automated assays, comparative assay performance remains limited.
Methods:
A subset of long-term frozen serum aliquots (n = 1021) from a previously reported clinical population representative of adults at risk or symptomatic for HBV infection was re-tested using the HBcT2 Atellica IM assay designed without the need for a retest zone. HBcT2 Index values obtained in 2020 and 2025 were compared by regression analysis and qualitative reactive/nonreactive interpretation agreement. The subset was also tested using the Roche Elecsys anti-HBcII assay on Cobas analyzer, and positive/negative percent agreements (PPA/NPA) were calculated to assess the methods agreement.
Results:
Strong linear relationships (slope, 0.98; Pearson's r, 0.993), and PPA/NPA > 99.5% between 2020 and 2025 HBcT2 Index values showed excellent agreement confirming the reliability of the archived clinical samples. Qualitative agreement (PPA/NPA) between the Atellica IM HBcT2 and Roche Elecsys anti-HBcII was high in the population overall (PPA/NPA's >96%) and among HBV categories (PPA/NPA's >90%).
Conclusion:
The Atellica IM HBcT2 assay on the Atellica IM analyzer demonstrated high qualitative agreement with an established comparator assay for detecting total anti-HBc antibodies, thus expanding the range of valuable diagnostic methods available for HBV laboratory testing. The results were comparable to the Roche Elecsys anti-HBcII assay in a high-risk/symptomatic population.
